万维提示：
1、投稿方式：在线投稿。
2、官网网址：https://diabetes.diabetesjournals.org/
3、投稿网址：http://mc.manuscriptcentral.com/diabetes
4、官网邮箱：diabetesjournal@diabetes.org（编辑部）
5、官网电话：(317) 354-1508（编辑部）
6、刊刊期：月刊，一个月出版一期。
2021年4月28日星期三
投稿须知
【官网信息】
Instructions for Authors
Manuscript Submission Form
A manuscript submission form must be completed for each article submitted. The form addresses ADA's policies on 1) originality and authorship, 2) copyright assignment, and 3) potential conflict of interest. The corresponding author should read the three sections, check the appropriate boxes, sign the document where indicated, and upload the completed form to the manuscript submission system upon article submission. ADA will accept ICMJE's Uniform Disclosure Form for Potential Conflicts of Interest.
Submissions will not be considered complete until the manusript submission form has been uploaded/received.
Statement of Originality and Authorship
Diabetes subscribes to the requirements stated in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals that authorship implies substantial contributions to conception and design or analysis and interpretation of data and drafting of the article or critical revision for important intellectual content. The editor reserves the right to query authorship contribution.
Any requested changes to authorship (addition or removal of an author) after the initial submission of a manuscript should be made in writing to the Editorial Office. The new author list must be provided, along with a justification for the change. The author(s) being added or removed should send separate correspondence consenting to the change.
Copyright Assignment
The American Diabetes Association (ADA) holds the copyright on all material appearing in Diabetes. All authors must check the appropriate boxes and sign the manuscript submission form, which transfers copyright to the ADA in accordance with the Copyright Revision Act of 1976.
Reuse and Post-Prints
ADA's manuscript submission form addresses permission policies related to reuse and post-prints. Please see below for the statement of provenance and other conditions:
Reuse. Authors are permitted to reuse portions of their ADA-copyrighted work, including tables and figures, in their own work, and to reuse portions or all of their ADA-copyrighted work for educational purposes, without submitting a request to ADA, provided that the proper citation and copyright information is given.
Post-prints. Authors are permitted to submit the final, accepted version of their manuscript to their funding body or institution for inclusion in their funding body or institution's database, archive, or repository, or to post the final, accepted version on their personal website. These manuscripts may be made freely accessible to the public upon acceptance, provided that the following two conditions are observed:
First, post-prints must include the following statement of provenance and, once the final version has been published in the journal, a link to the final published version of the paper on the journal's website:
This is an author-created, uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association (ADA), publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org.
Second, the version of the manuscript deposited or posted must be identical to the final accepted version, with the exception of the addition of the above statement and any changes necessary to correct errors. Authors may make changes to the posted version to correct mistakes or may issue an erratum at any time. However, the final published version of the manuscript may not be deposited, posted, or later substituted for the post-print.
Duality of Interest
All authors must read the ADA Policy Statement on Duality of Interest and check the appropriate box on the manuscript submission form, which can be found online and in every issue of Diabetes. Any author who has duality of interest to disclose must attach an additional statement that explains the nature of the duality or conflict of interest. Relevant duality or conflict of interest (or lack thereof) should also be disclosed in the authors'comments to the editor during the submission process.
Author Contributions: As of March 1, 2010, authors are required to include a paragraph in the Acknowledgments section listing each author's contribution. Example: "C.K. researched data. L.R. wrote the manuscript and researched data. H.N. reviewed/edited the manuscript. V.S. contributed to discussion and reviewed/edited manuscript. N.B. researched data and contributed to discussion. V.G. wrote the manuscript."
In addition, when authors cite the "editorial assistance" of a colleague, or help provided by a colleague "with preparing the manuscript," authors are required to list the employer/institution with which that colleague is affiliated. Example: "The authors acknowledge the editorial assistance of Mark Smith, Global Informatics, Inc., etc."; "The authors thank Mark Smith, Global Informatics, Inc,. for help with preparing the manuscript."
Color Figures
Beginning January 1, 2020, color figures no longer incur an additional processing fee. See FINANCIAL OBLIGATIONS FOR ACCEPTED MANUSCRIPTS for information regarding article processing charges.
Clinical Trials
All clinical trials submitted to Diabetes for consideration of publication must be registered. The International Committee of Medical Journal Editors (ICMJE) defines a clinical trial as "any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g., phase 1 trials), are exempt."
For definitions and further information, please see the section titled Obligation to Register Clinical Trials found in ICMJE's Uniform Requirements for Manuscripts Submitted to Biomedical Journals. Please note, however, that unlike ICMJE, ADA does not require trials to be registered before enrollment begins, although Diabetes does encourage this practice. When submitting your manuscript, please include the unique trial number and the name of the registry (e.g., ClinicalTrials.gov or ISRCTN) at the end of the abstract and in your cover letter.
Registries must be approved by ICJME. Approved registries include ClinicalTrials.gov, www.ISRCTN.org, www.actr.org.au, www.umin.ac.jp, and www.trialregister.nl.
Reporting on Human Islets
Effective January 1, 2019, Diabetes requires authors of papers reporting data obtained from studies on human islets to report critical characteristics of the human islets used for research (download the Human Islet Checklist). Such information will facilitate comparisons among studies using isolated human islets and, to the extent possible, standardization of the preparations and methods used by individual laboratories. These objectives are aligned with the current emphasis placed on scientific rigor and reproducibility in research by a number of major funding organizations (1,2). For full details, see the complete Human Islet Policy.
TOP
MANUSCRIPT FORMAT
Articles must be in clear and understandable English. Non-native English authors are encouraged to seek the assistance of an English-proficient colleague, or a communications agency such as “American Journal Experts”, to help improve the clarity and readability of a paper before it is submitted to the journal.
Every manuscript must have an accompanying title page. In addition to the full title, the title page should include a short running title (less than 47 characters and spaces); the first name, middle initial, and last name of each author; the affiliation (in English) of each author during the study being reported; the name, current affiliation, telephone number, and email address of the corresponding author; and the word count and number of tables and figures. The text on the title page should be center aligned.
The main text and tables must be saved in Microsoft Word document format, with 12 pt Times New Roman font, and the main text should double spaced with justified margins.
Please do not use headers, footers, or endnotes in your paper.
Original Articles
Original Articles are expected to present a significant advance in diabetes research and should be arranged in the following order: title page (first page), abstract (see below), introduction (no heading necessary), Research Design and Methods, Results, Discussion, Acknowledgments (including Author Contributions, Guarantor Statement, Conflict of Interest statement, funding, and Prior Presentation information), references, tables (each including a title and legend), and figure legends. Figure files and online supplemental files should be uploaded separately. Note: Methods should not be placed in the supplemental material in order to circumvent word count limits.
An abstract is required for all Original Articles. The abstract should be unstructured, concise and precise and should convey the essential findings of the manuscript. The abstract may not exceed 200 words. It should state the rationale, objectives, findings, and conclusions of the manuscript. References, primary data, and statistical significance should not be presented in the abstract, and nonstandard abbreviations must be defined. Authors are encouraged to include a statement that describes the potential translational impact of the study results.
The word limit for the main text of Original Articles that will appear in the print version of the journal is 4,000 words. (The total word count excludes the title page, abstract, acknowledgments, references, tables and figures, and table/figure legends.) However, word limit should not prevent authors from providing sufficient methodological and data analysis detail. Authors are encouraged to put additional needed detail into supplemental material. While this will not appear in print, it will be available online and as an addendum to the PDF when downloaded from the site. It should be labeled “Supplemental Material” or “Supplemental Data”.
The main text should be double spaced with justified margins.
The article should contain no more than 50 references and the reference section should be single spaced with justified margins.
The article should contain no more than a combination of eight tables and/or figures.
Supporting documents/data may be uploaded for review purposes and will not be published. (When uploading, be sure each file is clearly labeled "supporting document/data.")
Online supplemental material should be uploaded in a separate file for publishing in an online-only supplement. Please do not include supplemental material or supplemental figure legends in the main document. Very large datasets may be submitted as supplemental material and cited in the text with a URL to the material, hosted on an author-affiliated website or data repository, or may appear with a note that the data is available upon request to the author. Please see the corresponding sections below for further formatting information on supplemental online-only material, acknowledgments, references, tables, and figures.
Brief Reports
The Brief Report category can be used for any original research pertinent to the journal. The purpose of the category is to permit publication of very important, high-quality mechanistic studies that can be concisely presented. Brief Reports should be arranged in the following order: title page, abstract (see below), introduction (no heading necessary), Research Design and Methods, Results, Discussion, Acknowledgments, references, tables (each including a title and legend), and figure legends.
An abstract is required for all Brief Reports. (Please follow the formatting guidelines listed under Original Articles.)
The word limit for the main text of Brief Reports is 2,000 words. (The total word count excludes the title page, abstract, acknowledgments, references, tables and figures, and table/figure legends.) However, word limit should not prevent authors from providing sufficient methodological and data analysis detail. Authors are encouraged to put additional needed detail into supplemental material. While this will not appear in print, it will be available online and as an addendum to the PDF when downloaded from the site.
The report should contain no more than 25 references and the reference section should be single spaced with justified margins.
The article should contain no more than a combination of four tables and/or figures.
Supporting documents/data can be uploaded for review purposes and will not be published. (When uploading, be sure each file is clearly labeled "supporting document/data.")
Online supplemental material may be uploaded for publishing in an online-only supplement. Very large datasets may be submitted as supplemental material and cited in the text with a URL to the material, hosted on an author-affiliated website or data repository, or may appear with a note that the data is available upon request to the author. Please see the corresponding sections below for further formatting information on supplemental online-only material, acknowledgments, references, tables, and figures, and online supplemental material.
Review Articles
Diabetes considers two types of review articles: Methodological Reviews and Perspectives in Diabetes.
Methodological Reviews provide a comprehensive, critical perspective of research topics and/or methodological approaches that are highly relevant to investigators in the field of diabetes research. It should be interpretative rather than a summary, and should describe various available approaches as well as their relative merits, limitations, and specific applications.
Perspectives in Diabetes may highlight recent exciting research, not primarily that of the author(s), and may provide context for the findings within a field or explain potential interdisciplinary significance (similar to that of a Review Article). Invited Perspectives commenting on papers in Diabetes should add a dimension to the research and not merely be a summary of the experiments presented in the paper. It can also be a critical review that is more interpretational than a summary and, if justified by strong rationale, can propose novel hypotheses.
Reviews are invited or considered for submission based on a proposal from the author(s). Please review the Instructions for Submitting a Proposal, and contact Jane Castner (jcastner@diabetes.org) with any questions.
Commentaries
Commentaries are brief articles presenting the authors' views on a topic of current interest. Commentaries (and Editorials) are by invitation only.
Commentaries should be limited to 1,000 words, no more one than table and/or figure, and no more than 20 references. For further information regarding Commentaries, please read Commentaries in Diabetes, instructions for authors.
Manuscript Submission Tip: To bypass the Abstract field when submitting a Commentary, type None in the Abstract field. For more tips on uploading your manuscript, see the Manuscript Submission Tips section.
Online Letters to the Editor
Online Letters to the Editor are intended to provide an opportunity to comment on articles published within the previous three months in Diabetes. Online Letters to the Editor are not intended as a platform for presenting unpublished data, research, or observations.
While Online Letters are only published online, they are listed in the table of contents of the print version, and will be assigned an "E" page number. Citations for Online Letters should include the letter's unique DOI (digital object identifier) number, which is available in the footnote section of each letter (e.g., 10.2337/db08-XXXX).
Letters do not have abstracts and should not exceed 500 words and 5 references. The inclusion of tables or figures in letters is discouraged. As with all submissions, letters should be double-spaced with 12 pt. Times New Roman font and justified margins.
Letters must include a title page with the authors' full names and affiliations and the corresponding author's contact information.
For comments on or responses to another article or letter, the article or letter on which the letter comments or responds to should be included as reference 1 in the reference list. The editor reserves the right to ask authors of the cited article to respond.
Manuscript Submission Tip: To bypass the "Abstract" field when submitting a Letter to the Editor, type "None" in the "Abstract" field. For more tips on uploading your manuscript, see the Manuscript Submission Tips section.
……
